Is GLP-2 involved in weight loss?

No. Its described action is on the intestinal mucosa, not on appetite or glucose. Marketing that groups it with GLP-1 because of the shared name is trading on a similarity that does not extend to what the peptides do.

Do GLP-1 receptor agonists activate the GLP-2 receptor?

They are separate receptors and the agonists in clinical use are selective for their own. The peptides are related by precursor, not by receptor - which is exactly why the GLP-2 receptor had to be cloned independently.

Why is the STEPS trial so small?

Because short bowel syndrome with parenteral nutrition dependence is rare. Trial size is set by how many eligible patients exist, and 86 participants in a quadruple-masked randomised trial is substantial evidence in that context, even though the same number would be a Phase 2 in obesity.

Can GLP-2 be bought as research material?

It is not supplied on this site. Teduglutide is a licensed prescription medicine and is not a research chemical. Anything sold under either name outside a pharmacy is not the licensed product.

GLP-1 & Incretin Science

The Other Peptide the L Cell Releases

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-244 cited sources

GLP-2 is a 33-amino-acid peptide released from gut endocrine cells alongside GLP-1, from the same precursor protein. It promotes growth of the intestinal mucosa rather than affecting glucose or appetite, and its analogue teduglutide is licensed for short bowel syndrome.

Key facts

Length: 33 amino acids
Source: Gut endocrine cells, co-secreted with GLP-1
Precursor: Proglucagon, the same gene as GLP-1 and glucagon
Principal described action: Intestinal growth-promoting activity
Receptor: GLP-2 receptor, distinct from the GLP-1 receptor
Inactivating enzyme: DPP-4
Licensed analogue: Teduglutide
Pivotal trial: STEPS, NCT00798967, Phase 3, 86 participants, 24 weeks

Discovered by accident, like several of the best things here

Drucker's own account of the discovery describes it as following serendipitous observations that proglucagon-producing tumours induced intestinal growth in mice. That is a useful reminder about how this field advances: the observation came first and the mechanism was worked backwards from it. A tumour secreting the products of one gene made the gut grow, which meant one of those products had a growth-promoting action nobody had assigned to it. GLP-2 was the answer, and it is a 33-amino-acid peptide co-secreted with GLP-1 from the same gut endocrine cells.

Two peptides from one cell doing unrelated things

GLP-1 and GLP-2 are released together, from the same cell, in response to the same stimulus. GLP-1 acts on insulin secretion, gastric emptying and appetite. GLP-2 acts on the intestinal mucosa itself, promoting growth of the absorptive surface. They engage different receptors, and the GLP-2 receptor had to be cloned separately before development could proceed. The pairing is coherent if you think about what an L cell is reporting: nutrients have arrived. One response is to handle the nutrients metabolically, the other is to expand the apparatus that absorbs them.

The DPP-4 problem, and the one-residue solution

Drucker names the recognition of dipeptidyl peptidase-4 as a critical determinant of GLP-2 bioactivity among the key developments enabling pharmaceutical work. GLP-2, like GLP-1, is cleaved and inactivated by DPP-4, which cuts after the second residue when that residue is alanine or proline. Teduglutide is described as a simple GLP-2 analogue - the substitution of a single amino acid at position two removes the DPP-4 recognition site, and the resulting molecule survives long enough to be given once daily. The same enzymatic vulnerability and the same class of fix appear across this whole peptide family, which is why understanding DPP-4 explains the shape of so many of these molecules.

What teduglutide is licensed for

Short bowel syndrome, a condition in which so much intestine has been lost that absorption is inadequate and patients depend on parenteral nutrition. The pivotal STEPS trial is registered as NCT00798967: a Phase 3, quadruple-masked, 24-week study of 86 participants with parenteral-nutrition-dependent short bowel syndrome, with a responder analysis as its primary outcome. The clinically meaningful endpoint in this condition is reduction in the volume of parenteral support required, and a later analysis by Jeppesen and colleagues found that response was associated with baseline parenteral support volume, bowel anatomy and disease features - notably whether the colon remained in continuity. That is a small trial by obesity standards and a substantial one for a rare disease.

Why the growth effect is the interesting risk

A drug whose mechanism is promoting growth of intestinal mucosa raises an obvious question about growth that is not wanted, and that question belongs to the prescribing information and to specialist practice rather than to a reference article. The general point worth making is that GLP-2's mechanism is trophic in a way GLP-1's is not, and that this is the sharpest illustration available of why two peptides from the same precursor released by the same cell cannot be discussed as though they were interchangeable.

Where GLP-2 sits in current development

Interest in combining GLP-1 and GLP-2 activity in one molecule exists, on the reasoning that the precursor already pairs them. Whether that produces anything useful is unsettled. Teduglutide is a licensed medicine prescribed and monitored for a serious condition; it is not supplied on this site, nothing sold here is a version of it, and it is not relevant to weight management in any way. It appears in this library because it is the proof that a proglucagon-derived peptide other than GLP-1 can become a real medicine.

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is GLP-2 involved in weight loss?: No. Its described action is on the intestinal mucosa, not on appetite or glucose. Marketing that groups it with GLP-1 because of the shared name is trading on a similarity that does not extend to what the peptides do.
Do GLP-1 receptor agonists activate the GLP-2 receptor?: They are separate receptors and the agonists in clinical use are selective for their own. The peptides are related by precursor, not by receptor - which is exactly why the GLP-2 receptor had to be cloned independently.
Why is the STEPS trial so small?: Because short bowel syndrome with parenteral nutrition dependence is rare. Trial size is set by how many eligible patients exist, and 86 participants in a quadruple-masked randomised trial is substantial evidence in that context, even though the same number would be a Phase 2 in obesity.
Can GLP-2 be bought as research material?: It is not supplied on this site. Teduglutide is a licensed prescription medicine and is not a research chemical. Anything sold under either name outside a pharmacy is not the licensed product.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum